nyuci_ar10-11_mech29

7/30/2019 NYUCI_AR10-11_mech29

1/46

What do

TumbprintsMatchmaking

TreadDominoes

Flowers&ricycleshave in common?

NYU Cancer Insiue 2010/2011 Repor

7/30/2019 NYUCI_AR10-11_mech29

2/46

TumbprinsMicrobiomePg. 4

MachmakingChemical Biology

Pg. 8

Tread

Epigenetics

Pg. 12

Dominoes

Symptom & Pain Management

Pg. 16

FlowersCaring for the Caregiver

Pg. 20

ricyclesSurvivorship

Pg. 24

ELIMINATING

THE BURDEN OF

CANCER

7/30/2019 NYUCI_AR10-11_mech29

3/46

While seemingly diferent, all sixhave one thing in common. Tey all reect

unique discoveries that willhelp eliminate the burden o cancer.

NY U Cancer Institute is a clinical incubaorha exends beyond he radiional walls o anacademic medical cener o capialize on issynergisic relaionship wih he diverse culuraland socioeconomic landscape o New York Ciy.All o he images in his repor refec he spirio hese connecions ha are a he hear o our

organizaion. In he ollowing pages, you willsee examples o how he NY U Cancer Insiue ismaking seady progress oward eliminaing heburden o cancer, and how he noions o humb-prins, machmaking, hread, dominoes, fowersand ricycles are playing a signican role.

1NYU Cancer I nsiue 2010 / 2011 Repor

7/30/2019 NYUCI_AR10-11_mech29

4/46

WH AT

DIFFERENTIATES

US

Marix Pursui Focus Access

DiversiyCollaboraionHear Recogniion

Our srucure as he Ca ncer

Insiue a NYU Langone

Medical Cener, wih ies o he

larger Universiy, enhances

collaboraions and leverages accesso criical new echnologies.

NYU School o Medicines

Curriculum or he 21s Cenury

(C21) eaures an innovaive

new oncology curriculum.

Our eam osers a unique

relaionship beween reaing

physicians and laboraory

scieniss, driv ing he pursui

o mehods o neuralize hebiological pahways ha underlie

he origins o human cancer.

Tese eors are leading o novel

ways o preven and rea his

class o diseases.

Our clinical research ocus has

encouraged 20% o our paiens

o paricipae in herapeuic

clinical rials (naional average =

4% paricipaion), providingpaiens wih access o he bes

available herapies while dening

beter opions o improve oucomes.

Our a liaion wi h he New

York Ciy Healh and Hospials

Corporaions Bellevue Hospial

Cener and Woodhull Medical

and Menal Healh Cener aordsdisincive opporuniies o learn

and care or exraordinarily diverse

groups o paiens wih cancer.

Our locaion in he hear o New

York Ciy oers us access o a

one-o-a-kind urban laboraory

wih a unique global paien

populaion. I helps us o under-

sand variaions o cancers wihin

cerain populaions and allows

he Cancer Insiue o dene

and eradicae barriers o care orpaiens in our communiy.

Our culure o collaboraion

is reinorced hroughou he

Cancer Insiue and ranslaes

ino a rue wi llingness o our

eams o parner and conceive

o new mehods o preven and

rea cancer.

Our houghul approach o

balancing he needs o our paiens,

our communiy and our sa

remains a he hear o wha we do:

we care.

Our repuaion as an NCI-

designaed Cancer Cener, and

recogniion as one o he op 25

academic medical ceners or

cancer in he counry and one o

he op hree in New York, according

o U.S. News & World Reports

20112012 Bes Hospials, refec

our commimen o excellence.

2 NYU Cancer Insiue 2010 / 2011 Repor

7/30/2019 NYUCI_AR10-11_mech29

5/46

Join us orsix stories o discovery


7/30/2019 NYUCI_AR10-11_mech29

6/46


7/30/2019 NYUCI_AR10-11_mech29

7/46

THUMBPRINTS

Microbiome

90% o you is a uniquecommunity o bacteria.

rillions o baceria live in our bodies, ounumbering ourown cells by 10:1. Tese largely unexplored microbes areparicularly robus in our mouh, esophagus, somach andinesines. Now biomedical scieniss a he NYU CancerInsiue are discovering ha baceria, collecively knownas he microbiome, may play a pivoal role in developingcerain cancers and in he developmen o new reamens

and prevenive measures. One key objecive is o gure oui humans share a core microbiome prole, and i changesin he microbial populaion rigger changes in our healh.Evenually, he microbiome prole o each person asunique o an individual as heir humbprins could reveala grea deal o inormaion abou how we can gh diseaseand achieve healh. Because o his promising new direcion,he Naional Insiues o Healh (NIH) esablished heHuman Microbiome Projec, which has been awardingresearch grans or seleced projecs ha examine he

microbiome-disease connecion. Zhiheng Pei, MD, PhD,associae proessor o pahology and medicine, leads one o

he selec ew eams chosen in he Unied Saes oconduc demonsraion projecs on behal o he HumanMicrobiome Projec.

Linking changes in the microbiome to esophageal cancer

A signican game changer occurred wih he developmeno high-hroughpu sequencing ha led o he discovery o

many new ypes o baceria never beore recognized. Dr. Peiand his colleagues have colleced and sequenced baceriarom he esophagus in boh healhy elderly males and hosesuering rom gasroesophageal refux disease (GERD).Tey ound ha he mix o baceria was, indeed, dierenin he diseased esophagus. Te progression in Barretsesophagus is a muli-decade process characerized bygenomic insabiliy and accumulaion o molecular alera-ions in cells, bu he driving orce behind he geneicchanges is unknown, says Dr. Pei. Wha is known is ha

paiens wih Barrets esophagus have a 30-o-60-oldexcess risk o developing esophageal adenocarcinoma (EA)

NYU Cancer I nsiue 2010 / 2011 Repor 5

7/30/2019 NYUCI_AR10-11_mech29

8/46

Microorganismsounumber cells in he

human body

relaive o he risk o he general populaion. Despiehe decline in he incidence and moraliy raes ocancers in recen years, he rae o EA has increasedby more han 600% in jus he pas hree o ourdecades. In essence, Dr. Pei is invesigaing he heoryha chronic exposure o an abnormal microbiomein he esophagus is carcinogenic. Trough he NIH

Human Microbiome Projec gran, Dr. Pei is usinga specialized DNA sequencing echnique ha hedesigned o caalogue housands o bacerial srainsin a larger sample o paiens.

Linking the microbiome to other diseases Oheraculy members have been conducing innovaiveresearch as well. Marin J. Blaser, MD, he FrederickH. King Proessor o Inernal Medicine, and chair,Deparmen o Medicine, and proessor o microbi-

ology, has received recogniion or his pioneeringwork, which has deepened our undersanding o heconnecions beween Helicobacter pylori (H. pylori),

cancer and oher human diseases. O paricularnoe is his view ha H. pylori is someimes helpul(probably early in lie) and someimes harmul(probably lae in li e). Building on his early success,Dr. Blaser coninues o receive suppor or hiscreaive approaches o research, including a sudyunded by he Human Microbiome Projec o

assess wheher changes in he skin microbiome mayconribue o psoriasis, an infammaory skin disease.

Linking the microbiome to oral cancer In anoherprojec unded by he Naional Cancer Insiue,Dr. Pei and Richard B. Hayes, DDS, PhD, direcoro he Division o Epidemiology a NYU School oMedicine and associae direcor o populaionsciences a NYU Cancer Insiue, are looking inohe poenial connecion beween he microbiome

and cancers o he mouh and upper gasroinesinaland respiraory racs. Tey are examining oralsamples ha were colleced beore some o he

en


7/30/2019 NYUCI_AR10-11_mech29

9/46

paiens developed cancer. In comparing he pre-cancer bacerial proles wih he pos-cancerproles, hey are seeking o ideniy a possible associaion beween he changes in he microbiomeand he developmen o disease. Were rying o nd cause and eec. Why do some smokers gecancer and ohers do no? asked Dr. Hayes. I may be because some people may have enough ohe baceria in heir microbiome populaion ha acivae he carcinogens ha lead o disease.

Wih his poenial new paradigm, he hinking is shiing dramaically. Hisorically i was houghha a single pahogen caused a single disease. Bu i changes in he microbiome communiy are

responsible, new avenues o discovery and new reamens are possible, says Dr. Pei.

New treatment options Te sudy o he microbiome in he esophagus could yield paien oucome-associaed biomarkers o assess risk, which could guide esing requency. And i is shown hachanges in he microbiome rigger cerain cancers, docors could add probioic, or benecialbaceria, o he microbiome populaion, which could help resore a healhy microbial balance andweaken he eecs o he desrucive baceria. reamens may also include a combinaion oanibioics, probioic baceria, or prebioics, oods such as dieary ber ha simulae he growh obenecial baceria in he inesine. In he case o oral cancers, adds Dr. Hayes, We may nd haa powerul mouhwash may ulimaely be able o wipe ou bad baceria and resore a proper balance

ha will help paiens avoid disease.

One.


7/30/2019 NYUCI_AR10-11_mech29

10/46


7/30/2019 NYUCI_AR10-11_mech29

11/46

Finding the perectchemistry or science and lie.

I akes on average 10 o 15 years or more, and los oailures and misseps, o bring a single drug o marke, asmany cancer paiens and heir physicians wai anxiouslyor eecive or beter reamens. Jus siing hrough hemyriad o daa o esablish a clear saring poin in he drugdevelopmen process or cancers wih complex, muligeniceiologies is a major challenge. Bu now a new high-speed,

searchable chemical biology nework, in developmena he NYU Cancer Insiue, could sreamline his pro-cess signicanly by quickly nding maches beweencomplex geneic or proein-based molecular signaureso cancers and he millions o bioacive, small-moleculedrug compounds. Tis chemical nework projec, headedby imohy J. Cardozo, MD, PhD, assisan proessor opharmacology, is he rs o is kind, seeking o link molecu-lar signaures o disease o molecular reamens, and vice

versa. According o Dr. Cardozo, Drugs largely have o bind

o proeins expressed by genes in order o work. I soundssimple, bu nding maches has unil now been incredibly

complex, cosly and ime-consuming. Te sysem will be aweb-based inerace, modeled on public search engines likeYahoo! and Google. Personalized medicine invesigaorswill have a ool ha links arge molecular signaures, in heorm o liss o genes or proeins, emerging rom small, well-characerized sudies o paien groups o an exensive libraryo drug compounds, explains Dr. Cardozo. Te sysem no

only makes a mach, bu also provides scores agains all oherproein signaures. Medicinal and chemical biologiss andoxicologiss will also be able o direcly associae chemicalsrucures wih proein signaures o assess he viabiliy andoxiciy o poenial drugs well beore human rials begin.Tis knowledge avoids he ime in developmen and in rialswhen promising drug candidaes are ound o cause debili-aing side eecs. All he echnologies are available and inplace o immediaely deploy his work, Dr. Cardozo says.

Were building an easily usable, public websie ha will no

require a seep learning curve or busy biomedical research-ers. Tis is designed as a sel-service ool or he communiy

MATCHMAKING

Chemical Biology


7/30/2019 NYUCI_AR10-11_mech29

12/46

7/30/2019 NYUCI_AR10-11_mech29

13/46

o scieniss. Te sysem, which is expeced o be up and running by he end o 2012, willake advanage o compuaional and sysems biology and a growing library o daa gener-

aed by he Naional Insiues o Healh (NIH) Molecular Libraries Program. Te rs paro he daabase includes all poenial drug binding sies, or pockes in he human proeome,using compuaional modeling and srucural analysis echniques. Te second sep uses com-puaional molecular docking o cross-reerence hese drug-binding pockes wih he NIHsPubChem daabase, he comprehensive reposiory o more han 30 million small-moleculecompounds buil and managed by he Naional Cener or Bioechnology Inormaion.

Streamlining the drug development process Te need or his kind o searchable sysem iscriical, Dr. Cardozo says, noing ha he FDA recenly launched a Criical Pah iniiaiveo improve he speed and e ciency o he drug developmen process in order o bringeecive new reamens o paiens more quickly and a lower coss. Tis will be especiallymeaningul or paiens wih orphan or rare diseases, who may no have as many reamenopions, and are oen prescribed drugs ha may no represen heir specic reamen needs.o realize he benes o personalized medicine, he key is o ideniy he geneic proleso paiens requenly highly complex geneic daa now available because o breakhroughsresuling rom he Human Genome Projec ha correlae wih opimal herapeuicresponses. Essenially, he chemical biology nework would process one o hese proles,and a l is o biologically mached drug-like chemical compounds would insanly bererieved, says Dr. Cardozo. Lead drug compounds in early-sage developmen quicklyargeed o specic disease-relaed proeins could emerge rom his process, resulingin ewer ailures as well as shorer imes o validaion in clinical rials on more specic paien

populaions, wih more clearly recognizable end poins, explains Dr. Cardozo.

Realizing the promise o personalized medicine Such a ool should also have a prooundimpac on drug approval. Already we know ha he clinical rials o drugs mached o a singlegene or proein biomarker, such as he HER2/neu biomarker mached o Hercepin, proceedmore rapidly, and succeed more oen, a a grealy reduced cos. As researchers ideniy moresophisicaed genomic markers, he needs o smaller groups o paiens wih specic mua-ions ound in common cancers can be addressed more quickly in small, argeed clinicalrials. Tis would include paiens wih measaic melanoma, or example, who unil recenlyhave had limied reamen opions, says Dr. Cardozo. Personalized medicine invesigaors

who ideniy a subpopulaion up ron could uilize he knowledge direcly or drug discovery

and by exension or designing an appropriae personalized or argeed clinical rial. Tepoenial resul could be more and aser approvals or drugs a lower cos and risk, he says.

On he le:

A new high-speed searchable chemical

biology network, modeled aer search engines

like Yahoo! and Google, will help

scientists match specic medicines to specic

patients as never beore.


7/30/2019 NYUCI_AR10-11_mech29

14/46


7/30/2019 NYUCI_AR10-11_mech29

15/46

Your lie is written on a thread,which can be unraveled and read.

en or 15 years ago, mos biomedical scieniss didn knowabou epigeneics: he sudy o changes in gene expressioncaused by he surrounding nework o proeins ha is associ-aed wih he DNA helix, raher han modicaions in heDNA sequence isel. Bu all ha is changing dramaically ashe NYU Cancer Insiue builds a body o knowledge hais leading o innovaive reamens or cancer. Unil recenly,

scieniss have appreciaed ha genes and environmenalacors worked in parallel o infuence a persons biologicalmakeup, including a predisposiion o cerain diseases. Nowscieniss are recognizing he inerplay beween environ-men and inheriance in much greaer deail. No only aregenes infuenced by he environmen, hey acually receiveinsrucions on where and when o ac. And hanks ohigh-hroughpu echnologies we have begun o read heseinsrucions, which acivae or deacivae genes in responseo changing condiions. Te insrucions are no encoded in

he DNA sequence (genome), bu in oher molecular sruc-ures associaed wih he chromosomes (epigenome). TeNaional Insiues o Healh, which considers epigeneics

a new ronier o science, has been invesing $190 milliono accelerae research, because is now widely accepedha he origins o healh and suscepibiliy o disease are,in par, he resul o epigeneic regulaion o he geneicblueprin. Cancer scieniss, in paricular, are on he ronlines o his new ronier, learning o manipulae epigeneicmarks ha urn o some genes (umor suppressors, or he

brakes or cancer) and jump-sar ohers (oncogenes, orhe acceleraors o cancer). Several leading researchers a heNYU Cancer Insiue are helping o dene his imporaneld o sudy, ocusing on how epigeneic code is regulaedby environmenal acors ha rigger cerain cancers, as wellas he developmen o innovaive agens ha aler epigeneicregulaion, which could lead o less oxic cancer reamenshan hose currenly available.

Understanding epigenetic mechanisms Danny Reinberg,

PhD, proessor o biochemisry and a Howard HughesMedical Insiue invesigaor, has been sudying epigeneicmechanisms, ha is, he regulaion o gene expression

THREAD

Epigenetics


7/30/2019 NYUCI_AR10-11_mech29

16/46

7/30/2019 NYUCI_AR10-11_mech29

17/46

developmen. Die and exposure o environmenal chemicals, among oher acors, hrough-ou all sages o human developmen, can cause epigeneic changes ha may urn on or urno cerain genes. His work is building on he mouning evidence ha a growing lis o envi-ronmenal carcinogens, such as nickel, induces changes in epigeneic programs. Nickel is acomponen o air polluion caused by he burning o oil. Te greaer he polluion, he greaer

he exposure o nickel pariculaes, and hehigher he incidence o lung cancer.

One sudy ocuses on he colleced lympho-cyes rom nickel renery workers andindividuals in China who have had a very

high ambien exposure o nickel. Werending ha he workers exposed o nickelhave dramaic changes in heir epigeneicproles, says Dr. Cosa, which is helpingus undersand changes in gene expressionollowing occupaional or environmenalexposure o nickel. Dr. Cosa believes hanickel inacivaes a umor suppressor gene,

which normally sops rampan cell growhand can lead o lung and nasal cancers.

Undersanding he naure o meal-inducedepigeneic eecs will shed ligh on changesduring carcinogenesis, leading no only

o early deecion bu also o prevenion sraegies and biomarker developmen, saysDr. Cosa. Niney-ve percen o lung cancer is aal because is no caugh early enough.I we have he ools o cach i early, we can save lives.

Agents o change Docors a he NYU Cancer Insiue are in he process o developingnovel epigeneic reamens or various hemaologic malignancies, including lymphomasha occur in aduls and leukemias in children. Invesigaors have deermined ha aberranhisone aceylaion and DNA mehylaion are requenly observed in human cancer, conrib-

uing o umor progression and correlaing wih drug resisance. Work in he laboraory oWilliam L. Carroll, MD, he Julie and Edward J. Minsko Proessor o Pediarics, proessoro pahology and direcor o he NYU Cancer Insiue, has shown ha reaing relapsedleukemia cells wih hisone deaceylase and DNA mehylranserase inhibiors can repro-gram a reracory geneic signaure and resore sensiiviy o convenional chemoherapy.He and his colleagues have jus iniiaed a naionwide sudy o rea children wih relapsedacue lymphoblasic leukemia. Tese new drugs may be combined wih radiional chemo-herapy o creae a more powerul and eecive reamen, Dr. Carroll says a synergisicapproach o available reamens ha can be applied o oher cancers.

On he le:

Gene-expression proling and the

spectrum o genes turn on or of under

diferent disease-specic contexts.

Te genetic signaling in the cell ows

through primary, secondary and tertiary

signaling hubs, with varying degrees

o importance in cancer development.


7/30/2019 NYUCI_AR10-11_mech29

18/46


7/30/2019 NYUCI_AR10-11_mech29

19/46

One symptom leads to another.Finding ways to ease the burden.

Brian L. Schmid, DDS, MD, PhD, proessor o oral andmaxilloacial surgery and direcor o he Bluesone Ceneror Clinical Research a NYUs College o Denisry, is alloo amiliar wih he inensiy o cancer pain. So are henurses, social workers, nuriioniss, psychologiss andpsychiariss a he NYU Cancer Insiues muliple rea-men ceners. While hese healhcare providers can ell

counless sories o healing and relie, hey also know abouhe pain ha prevens paiens rom engaging in everydayaciviies. Unaddressed, his kind o pain, wheher causedby disease or reamen, can disconnec people rom whohey are and lead o oher problems, like sleep deprivaion,anxiey and depression. Like one domino knocking overanoher, one sympom can rigger ohers, someimes inclusers, making hem even more di cul o rea, saysFrances Carwrigh, PhD, RN, AOCN, senior direcor onursing or oncology services and medicine. Te opporu-

niy lies in argeing inervenions so ha alleviaing onesympom in a cluser will relieve muliple relaed sympomsa he same ime. While many people misakenly equae

palliaive care wih hospice, oday we know ha heerm palliaive care reers o managemen o sympomsregardless o disease sage.

Easing the burden Cancer or many paiens represensa loss o conrol, which is why we do everyhing we cano help, including lisening and allowing hem o share heir

burden. I also helps paiens eel less alone in he process,explains Karen G. Langer, PhD, clinical associae proessoro rehabiliaion medicine, and manager, Supporive ServicesProgram a he Cancer Insiues Clinical Cancer Cener.

Is a ull-ime commimen, agrees Laura J. agliareni,PhD, sa psychologis a NYU Langones Sephen D.Hasseneld Childrens Cener or Cancer and Blood Disorders.

Our sa does whaever i akes o help ease he burden.For psychologiss and social workers, his dedicaion isnonly abou sensiive paien advocacy, i also includes

suppor by providing individual or group counseling o dealwih pain, depression, anger and anxiey a various sageso heir reamen.

DOMINOES

Symptom & Pain Management


7/30/2019 NYUCI_AR10-11_mech29

20/46

{ }

In addiion o alleviaing he burdeno pain, our comprehensive programs

or sympom managemen aredesigned o also suppor naionwide

eors o reduce morbidiy,hospial says, repeaed admissions

and insurance coss.


7/30/2019 NYUCI_AR10-11_mech29

21/46

Finding new treatments As hese proessionalsocus daily on easing pain and suering, painmanagemen medicaions haven kep up wihadvances in cancer reamen, says Dr. Schmid.

oday, docors sill rely on high doses o narcoicsand nonseroidal ani-infammaory drugs. Teseanalgesics yield limied relie and may have signicanside eecs. Dr. Schmid believes ha oral canceris a logical place o sar he search or new rea-mens. Oral cancer is very painul, bu he pain isa an accessible, primary sie, so sampling he cancer

microenvironmen is relaively easy. Duringsurgery o remove he oral cancer, Dr. Schmid willplace a probe ino he issue o es i or proeinsand pepides ha produce pain. He is also askingoral cancer paiens o repor on heir pain levels in asudy unded by he Naional Insiues o Healh(NIH) hrough he Bluesone Cener.

Dr. Schmid laer validaes paien responses byideniying which o he sampled cancer molecules

correlae wih he paiens repored pain. Wih abeter undersanding o cancer pain mechanismscoming ou o he sudy, we hope o spur hedevelopmen o new medicaions ha can blockhose mechanisms, says Dr. Schmid. He andohers believe ha wih newer, argeed medicaionso reduce or eliminae cancer pain, oher sympomsin he cluser, such as sleeplessness and depression,may also subside, helping o improve he paiensqualiy o lie.

Working collaboratively Meanwhile, a ew blocksaway, mulidisciplinary eams wihin he CancerInsiue are reinorcing he imporance o raisingpain awareness among sa and orging new relaion-ships o improve pain and sympom managemen.In ac, Dr. Carwrigh and her NYU College oNursing colleague, Marilyn Hammer, PhD, DC,RN, are collaboraing wih Dr. Schmid on buildinga sympom managemen program and nding beter

ways o manage sympoms hrough he Cancer

Insiues evolving care model. Buoyed by heseclose relaionships, he NYU College o Denisry isnow sharing a $1.25 million NIH gran or cancer

pain research wih he Boson Biomedical ResearchInsiue. NY U has always worked on many ronsbringing clinical, educaional and research disci-plines ogehero develop he mos coordinaedapproach o pain and sympom managemen. Tas

why Im here. NYUs collaboraive environmen isinspiring, says Dr. Schmid.

Treating symptoms proactively Wih his col-laboraive environmen, he Cancer Insiue isachieving promising resuls hanks o he dedica-

ion o is inerdisciplinary eams, which no onlyinclude clinical sa bu also massage herapiss,acupuncuriss and yoga insrucors. Paiens ahe Clinical Cancer Cener are reporing benesrom our inegraive approach, repors James P.Fraiman, MD, clinical assisan proessor o psy-chiary and direcor o psychosocial services a hecener. Paiens who receive massage herapy whilereceiving chemoherapy have described reducionsin pain, nausea and anxiey. Cancer survivors also

say ha atending yoga classes has improved heirsense o well-being, he adds. Joan S. Scagliola,MSN, RN, direcor o oupaien oncology opera-ions, is commited o coninuing o expand heinegraive healh services available o paiens andbuild upon he services already available hroughouhe Medical Cener. A he Sephen D. HasseneldChildrens Cener, paien suppor and sympommanagemen may involve child lie specialiss,dieiians, recreaion and music herapiss, and aull-ime eacher o help young paiens keep up

wih school. Te Cener even boass a airy wihpurple wings in realiy a yoga and mediaioneacher who guides young paiens and heir amiliesin he Family Wellness Room. Tese programsare unded by generous suppor rom he Mak ingHeadway Foundaion, he Hasseneld Commitee,and he Chillin wih Adam: Te Adam GaynesFoundaion Inc. As a ranslaional cancer insiuewe do all we can o undersand he physical, psy-chological, social and spiriual aspecs o care and

how we can use his inormaion o arge sympomdisress, says Dr. Carwrigh. Tis is inegral o ourmission o providing personalized care.


7/30/2019 NYUCI_AR10-11_mech29

22/46


7/30/2019 NYUCI_AR10-11_mech29

23/46

aking care o you, so that you cantake care o your loved ones.

Survival raes or many cancers have improved, bu survi-vors oen sill need varying degrees o care, even ollowingsuccessul reamens. Ta means he helpul amilymember or riend becomes a primary caregiver, a criicalsupporive role during and aer herapy is compleed.

Wih his key responsibiliy, caregivers can have a prooundimpac on he survivors qualiy o lie, helping he survivor

avoid complicaions and even reduce he lengh o hospialsays. Bu caregivers can be hrus ino he role unexpec-edly, aking on responsibiliies or which hey may no eelprepared, says Vicoria H. Raveis, PhD, a research proessorin he Deparmen o Cariology and Comprehensive Care,and direcor o NY U College o Denisrys newly esab-lished Psychosocial Research Uni on Healh, Aging andhe Communiy. Tey may experience a range o emoions,including anxiey, anger and sadness, even as hey ry ocare or heir loved one, she says.

Tailoring programs and services Ulimaely, Dr. Raveissays caregiving can cause caregivers a grea deal o sress,oen resuling in sleep disorders, poor eaing and he neglec

o heir own healh and personal problems. Undersandinghe impac o cancer on he amily is si ll evolving, saysDr. Raveis. Limied research has been ocused on amilycaregiving during cancer survivorship, and litle atenionhas been direced oward ailoring programs and servicesha address postreamen inormal care, paricularlyor hose growing populaions experiencing he greaes

cancer burden

minoriies and he elderly, she explains.Recognizing hese challenges, he NYU Cancer Insiueconinually looks or ways o suppor caregivers. Dr. Raveis iscurrenly involved in wo major research projecs ocusingon he issue. One iniiaive, called Enhancing FamilyCaregivers Srenghs and Skills in Managing Older CancerPaiens Sympoms, deals wih supporing amily caregiverswho are addressing he needs o older cancer survivors.Dr. Raveis and her eam are no only invesigaing hepracical issues o adaping o he cancer diagnosis and

survivorship, hey are also developing evidence-based,amily-cenered, psychoeducaional and healh inerven-ions, argeing diverse and medically underserved

FLOWERS

Caring for the Caregiver


7/30/2019 NYUCI_AR10-11_mech29

24/46

communiies. Trough NYU Langones oupaienprograms, a liaes and communiy-based parners, here is

easy access o diverse groups who inensely experience heburden o cancer. NYU also oers an inerdisciplinaryresearch and care eam model or clinical and communiy-based survivorship sudies, says Dr. Raveis.

Providing skills and health literacy Te rs phase ohe program ocused on ideniying and helping 220 low-income amilies, locaed hroughou New York Ciy, whoseek care in communiy healh ceners. Final ollow-upassessmens wih paricipans are being compleed. In hesecond phase, wih suppor rom he Naional Insiueso Healhs Naional Cancer Insiue (NCI), Dr. Raveisand her eam are working wih caregivers recruied romnaurally occurring reiremen communiies (NORCs)communiies and neighborhoods around New York wherelarge numbers o people have sayed ino heir senior

years. Boh phases o he program are designed o provideproblem-solving skills and improved healh lieracy or care-givers who are rying o manage sympoms and care needs.Te sessions are designed o srenghen skil ls in he environ-men by helping caregivers undersand and use exper healh

inormaion, how o access available supporive resourcesand plan needs more eecively. Once he paien is homeand conac wih medical providers is limied, he problem-solving and communicaion skills o amily members areesed, says Dr. Raveis. By delivering educaional and sup-porive inervenions hrough exising communiy ceners,

we hope o help caregivers improve he qualiy o lie andqualiy o care or survivors and hemselves. Followinghese inervenions, we will analyze resuls, and i success-ul, will use he program as a model or ohers. Te sudyis expeced o be compleed in 2012.

Working through cultural diferences and amily dynamics

Beyond he basics, oher acors can exacerbae he caregivers

di culies. In some culures, or example, paiens areexpeced o endure chronic pain, says Dr. Raveis. Bu i wecan address culural dierences and sympom managemensensiively, qualiy o lie may improve signicanly. Helpingcaregivers work hrough he dynamics o amily relaion-ships in a postreamen environmen can also help improvecare and reduce sress. When adul children ake care oelderly parens, or example, issues abou personal conroland dependency, role reversal and ears o moraliy canarise. Te emoional rauma o cancer in a amily heighensexising ensions, impacing every aspec o amily relaion-ships and causing everyone o eel especially vulnerable,says Dr. Raveis. Since he program addresses all o heseissues, iniial survey resuls indicae ha caregivers are verysaised wih he program.

Changing the role o senior centers Anoher ground-breaking program Dr. Raveis is leading, An Academicand Communiy Parnership o ransorm Senior Cenerso Wellness Ceners, explores he idea o making seniorceners more relevan o he infux o aging baby boomers,

who are racing oward heir senior years. Te goal is opromoe healhy aging and o reposiion senior ceners asceners o wellness. Te program is a collaboraion beweenhe Council o Senior Ceners and Services o New YorkCiy, Inc. Working in conjuncion wih Mayor BloombergsAge-Friendly NYC: Enhancing Our Ciys Livabiliy orOlder New Yorkers, we are rying o posiion he ciyssenior ceners o become ceners o wellness, incorporaingsae-o-he-science public healh and medical research onhealhy aging and wellness in heir programming, saysDr. Raveis. By undersanding he needs and ideniying

barriers in hese populaions, we hope o develop appropriaecommuniy-based inervenions ha susain healh andenhance qualiy o lie.

On he righ:

Caregivers may experience a range

o emotions, including love,anger and hope, even as they try

to care or their loved one.


7/30/2019 NYUCI_AR10-11_mech29

25/46


7/30/2019 NYUCI_AR10-11_mech29

26/46


7/30/2019 NYUCI_AR10-11_mech29

27/46

Laura Hogan, MD, was only hree years old in 1981when she was diagnosed wih acue lymphocyic leukemia(ALL). oday, more han 30 years laer, shes a pediariconcologis reaing children wih he disease she hadand shes a research scienis spending counless hourssudying is eecs on survivors and looking or new rea-mens. I was oo young o undersand jus how sick I was

when I was diagnosed, she says, bu I remember missingschool, going o he hospial on holidays, and dealing wihhe nausea, evers and hair loss ha came wih he reamen.I also clearly remember eeling dieren, because oherchildren weren going hrough his.

Improving success rates Success raes a he ime werenso good, eiher. Beore he 1970s, ewer han 15% o childrensurvived ALL. Wih he successul inroducion o chemo-herapy drugs, however, survival raes began o climb,

especially as physicians learned o use muliple chemoherapydrugs in eecive new combinaions. Beter supporive care

helped oo. Despie all he challenges, Dr. Hogan was ableo regain her childhood. She did well in school and goinvolved in spors. And, she says, i didn ake long or hero decide o become a pediaric oncologis, o help oherchildren like her. I had grea relaionships wih he docorsand nurses who were reaing me, who cared or me. I hinkha really infuenced my decision, and I never really

changed my mind as I grew up, Dr. Hogan explains. I enjoymy work, is remendously rewarding, she adds, bu isalways di cul o see kids who are sick and o speak wihheir parens, who are so scared. I helps when I ell hem Ivebeen hrough he same hing. I gives hem some hope. Andnow, as he moher o wo young children, I can relae o heexperience in a oally new way. Bu Dr. Hogan doesn

jus care or children who ace he same ype o leukemia sheonce had. As a S. Baldricks Fellow, shes also par o heeam in he laboraory o William L. Carroll, MD, sudying

he causes o ALL relapse and he mechanism ha makesrelapse dieren rom he original disease. Dr. Carroll, he

When the patientbecomes the doctor.

TRICYCLES

Survivorship


7/30/2019 NYUCI_AR10-11_mech29

28/46

Julie and Edward J. Minsko Proessor o Pediarics,proessor o pahology and direcor o he NYUCancer Insiue, is one o he leading auhoriieson ALL and he ounding chair o he ChildrensOncology Group (COG) Commitee on ALL. COG,sponsored by he Naional Cancer Insiue (NCI),is he worlds larges childrens cancer researchcollaboraive. While childhood leukemia oday hasan overall survival rae o 80%, chemoherapy issimply no as eecive he second ime around in he20% o paiens who have relapses. Dr. Carroll s

lab has ound ha cerain genes appear o riggerhe relapse, making hem poenial arges or newherapies, which is very promising, Dr. Hogan says.

Helping survivors ace risks I has no enough,she also works on assessing he long-erm eecs ocancer reamen o help paiens achieve long-ermhealh. In 2008, in ac, she helped creae a long-erm ollow-up clinic a NYU Langones Sephen D.Hasseneld Childrens Cener or Cancer and Blood

Disorders, aimed a helping survivors o childhoodcancer, and heir amilies, undersand and prepareor he addiional healh risks hey ace, which mayinclude secondary cancers, oseoporosis and oherdiseases due o he lingering eecs o chemoherapyor radiaion. Concerns or children recenly reaedalso include such eecs on he brain and behavioras cogniive delays, atenion and learning disorders,anxiey and poor school perormance. No oneold Dr. Hogan abou residual eecs when she wasreaed because, in he early 1980s, you were lucky

jus o survive, she says. And many o he long-erm risks o childhood cancer reamen werenknown. A sudy unded by he NCI, he ChildhoodCancer Survivor Sudy, deermined ha mos adulswho experienced childhood cancer do no receiverecommended long-erm monioring.

Receiving long-term monitoring Many simply areunaware ha hey should, and primary care physi-cians are oen no amiliar wih he special needs ohese paiens. Since he kids who develop ALL are

so young, wih so many years ahead o hem, isimporan or survivors o see docors who under-sand he phenomenon and know wha he risks are,so hey can be screened and reaed properly, saysDr. Hogan, who now divides her ime beween herconinued research collaboraion wih NYU CancerInsiue and SUNY Sonybrook Cancer Cener.

A Hasseneld, paiens are eligible or he long-ermollow-up clinic wo years aer cancer reamenends, when hey receive a comprehensive hisorical

and physical analysis, as well as nuriional, psycho-logical and physical ness counseling, even inoadulhood. Wih appropriae, ongoing monioringand our cenralized approach, childhood cancersurvivors can do exremely well, says Dr. Hogan,

jus as she has. Tiry years aer her remission,Dr. Hogan admis o having a unique perspeciveha inorms her work. And someimes a paien willeven say, Look a Dr. Hogan. Im going o grow upand be like her.


7/30/2019 NYUCI_AR10-11_mech29

29/46

85%

survive ve years ormore in

Less than 5%survive more than ve

years beore 7

SURVIVAL RATE OF CHI LDRENWITH ACU TE LYMPHOCYTIC L EUKEM IA

BEFORE 1970 VERSUS 2010


7/30/2019 NYUCI_AR10-11_mech29

30/46


7/30/2019 NYUCI_AR10-11_mech29

31/46

In the study and treatment o cancer,the key elements are human compassion and

scientic rigorthe compassion toheal sick people, to help our patients and their

amilies overcome a di cult disease, and

the determination and discipline todevelop powerul new tools to do the job.Both are at the core o who we are at

the NYU Cancer Institute.

A M ESSAGE F ROM TH E DI R ECTOR

William L. Carroll, MD


7/30/2019 NYUCI_AR10-11_mech29

32/46

Every member o thisorganization takes on apersonal mission to eliminatethe burden o cancer in

whatever way they can, and

Im proud o the remarkablededication and care they

bring to the challenge,especially today, as we realizesignicant progress in

our understanding o cancerbased on years o hardscientic inquiry.

Wih hese inspiring proessionals as our oundaion,weve creaed a cancer insiue ha is making greasrides in ranslaing whas being learned in helab o deliver he mos eecive cancer reamensavailable. o accelerae our progress even urher,we coninue o look or ways o opimize ourmulidisciplinary programs. In 2010, we compleeda reorganizaion ha esablishes ve primary areaso invesigaion, which are insrumenal in ranslaingdiscovery ino clinical pracice. Tese areas include:

Cancer arges and Novel Terapeuics

aking

promising medicines rom laboraory concepshrough Phase I developmen and evenual approvalor clinical use.

Communiy and Environmenreaching ouo he diverse communiies o New York o makesure we undersand he people we serve and heimpac o heir environmen on healh in order oimplemen cancer prevenion sraegies.

Inegraive Healhcombining radiionalmedicine, behavioral science and new inegraiveherapies, such as massage, acupuncure andnaural herapy, o ease he burden o disease onpaiens and caregivers.

Molecular Oncology/Cancer Genomicsanalyzing, in unprecedened ways, he eaures ohe hos and umor, o creae a unique ngerprino every umor and paien, in order o arge he

mos promising reamen opions.

Immune- and Sem-Cell-Based Terapiesharnessing he immune sysem wih herapeuicsha srenghen he bodys resisance o disease,including new vaccines and cell-direced herapiesha direc a paiens own cells o atack umors.


A Message rom he Direcor

7/30/2019 NYUCI_AR10-11_mech29

33/46

Turning of the cancer switch Wih he exraordi-nary advances in biomedical science, we know hacancer is a much more personal disease han weonce hough in many ways like a breahingorganism wih a geneic code all is own. Breascancer, or example, is probably dozens, i nohundreds, o dieren diseases, wih housands omuaions. While hese numbers sound dishearen-ing, our growing knowledge abou he complexiyo disease energizes us, because were now able oprole each umor and undersand he mechanisms

ha creae i, which is helping us nd ways o urno he cancer swich. In ac, I believe ha aerachieving some progress over he decades, biomedi-cal science is in he process o aking a big seporward. And he Cancer Insiue, in paricular,is playing a key role.

Aer years o invesigaion, he pieces are comingogeher. Unleashing he poenial o he epigenomeis a grea example, as you see in he pages o his

repor. Our progress in breaking he epigeneic code,which acivaes or deacivaes genes in ways wenever undersood beore, is nohing shor o exraor-dinary. Wih his knowledge we are esablishing anew ramework or undersanding, prevening andreaing cancer, as well as how o promoe wellnessmore eecively. Combined wih advances inchemical biology, were now able o mach exisingand emerging drug compounds o specic umors inways ha were considered impossible previously.o pu i meaphorically, were no jus cuting o he

branches and leaves o his disease, were rying opull ou he roos.

360-degree perspective Wih basic scieniss whoare clinicians and clinicians who are scieniss, heCancer Insiue has a 360-degree perspecive onhe process o discovering and developing new cancerreamens o help our paiens and cancer paienseverywhere. Given he complexiies o our work,however, we undersand ha no single person or lab

a he Insiue can have all he answers. So weemphasize a culure o eamwork o mee hechallenge, wih cancer researchers and physicianscoming ogeher o share ideas and solve problemswih scieniss in he elds o chemical biology,denisry, nursing, environmenal science and manyoher disciplines.

As par o an exraordinary universiy, we also haveaccess o a range o resources and alen beyond hescope o he Medical Cener. As a resul, we can ap

ino he laes developmens in everyhing romhealhcare economics and law, o organic chemisry,o compuaional mahemaics and compuer science,o he role o he ars in paien recovery. And as aleader in a naional eor, we work cooperaively wihmany oher major cancer research ceners acrosshe counry, sharing wha weve learned and workingin andem o move he science and reamen ocancer orward, or he betermen o all humanbeings. Tese are jus some o he reasons why he

NYU Cancer Insiue is a highly versaile insiu-ion where grea hings are happening, and I couldnbe more enhusiasic abou our uure and ourconribuion o research and he mos promisingnew reamens.

Te oher reason or my enhusiasm, which I men-ioned a he beginning o his leterare heproessionals and sa o his Insiue, who obses-sively care abou easing he burden o cancer orour paiens, heir amilies and he communiies

around us. o his exraordinary eam o colleaguesand our ireless communiy o supporers, I wano express my deepes hanks or heir passion andexraordinary commimen o educaion, researchand paien care.

William L. Carroll, MDJulie and Edward J. Minsko Proessor o Pediarics;

Proessor o Pahology,NYU Langone Medical CenerDirecor, NYU Cancer Insiue

NYU Cancer I nsiue 2010 / 2011 Repor

A Message rom he Direcor

31

7/30/2019 NYUCI_AR10-11_mech29

34/46

Our mission is

origins o humanthat knowled

the personal ano cancer in o

the nation a


NYU Cancer Insiue

7/30/2019 NYUCI_AR10-11_mech29

35/46

to discover the

cancer and to usee to eradicate

societal burdenr community,

d the world.


NYU Cancer Insiue

7/30/2019 NYUCI_AR10-11_mech29

36/46

RESEARCH

HIGHLIGHTS

Te momenum coninues as our invesigaors srive

o discover he origins o human cancer and o use ha

knowledge o eradicae he personal and socieal burden o

cancer in our communiy, he naion and he world.

Heres a glimpse ino jus a ew o heir accomplishmens:

Pathways Iannis Aifantis,PhD, and his laboratory teamdiscovered ha he Nochpahway, known o be a rigger

in cell leukemia, can swichsides and be a umor suppressorin anoher ype o leukemia,called chronic myelomonocyicleukemia. Tese ndingssugges ha reacivaion o heNoch pahway can suppresssome leukemias.

Nature: May 12, 2011

Matrix Te laboratoryteam of Nina Bhardwaj, MD,

PhD, ound ha melanoma cellssecree MMP-2 (marix meal-

loproeinase-2), which is par oa group o enzymes ha breakdown proeins. Tese enzymesaler he uncion o key seninelsin he immune sysem knownas dendriic cells. Teir workhas also promped a collabora-ion wih indusry o evaluaehe eec o MMP-2 inhibiorson melanoma in preclinicaland clinical sudies.

Cancer Cell: March 8, 2011

Catalysts N-Ras and H-Rasare imporan oncogenesgenes ha have he poenial ocause cancer. Working wih

he immunophilin FKBP12,researchers rom he laboratoryteam of Mark R. Philips, MD,

ound ha modicaions oH-Ras may provide a novel her-apeuic arge o inhibi Ras-dependen umor developmen.

Molecular Cell:January 21, 2011


Research Highlighs

7/30/2019 NYUCI_AR10-11_mech29

37/46

Combinations Locallyadvanced breas cancer is a laesage and di cul o rea ormo he disease ha is responsible

or he majoriy o worldwidebreas cancer cases and deahs.Agroup led by Silvia C. Formenti,

MD, he Sandra and Edward H.Meyer Proessor o RadiaionOncology, repored an econom-ically easible herapeuicapproach ha simulaneouslycombines radiaion herapyand chemoherapy.

Breast Cancer Research andTreatment: December 2010

Orchestration Cilia, micro-scopic hairlike projecions onhe suraces o some cells,ac as anennae o orchesraekey signaling pahways. Deecsin primary ci lia can play arole in several geneic diseases,including hose ha mayunderlie cancer. New work byBrian D. Dynlacht, PhD, and

his laboratory team providedclues oward undersanding hemolecular mechanisms involvedin primary cilia assembly.

Cell: June 10, 2011

Robots Danil V. Makarov,MD, MHS,and collaboratorsexamined he change in numbero radical prosaecomies (RP)

beore 2001 versus aer 2005when use o surgical robos hadbecome more common. Teyound ha an increase in roboacquisiion was associaed

wih increases in he numbero RPs a he regional andhospial levels.

Medical Care: April 2011

Cooperation Eva Hernando-Monge, PhD, and the Inter-

disciplinary Melanoma

Cooperative Group ideniedhe role specic microRNAs(miRNAs) play in causingcancer cells o invade issue anda he same ime shu down anindividuals abiliy o ghabnormal cells. Tese ndingsmay lead o he argeingo specic miRNAs as a hera-peuic approach.

Cancer Cell: July 11, 2011

Maintenance Geneic insa-biliy can cause umors whenhe gain or loss o genes blockshe checkpoins ha mainain

a normal se o chromosomes.Building upon recen workrom he Dynlach laboraory,

MichelePagano, MD, he MayEllen and Gerald Jay RiterProessor o Oncology, and hislaboratory team idenied andcharacerized a gene (cyclin F)ha can manage and limielemens ha ulimaely im-pac he developmen andgrowh o umors and mainaingeneic sabiliy.

Nature: July 1, 2010

Mediators cells mediaedrom ransplaned bone marrowcan atack leukemic cells as wellas he hos.Michael L. Dustin,PhD, he Muriel G. and George

W. Singer Proessor o MolecularImmunology, and his laboratoryteam discovered ha inhibiinghe enzyme proein kinaseC-hea augmens he aciviyo regulaory cells ha canselecively suppress he atackon he hos and may hus bea useul herapy in combinaion

wih bone marrow ransplana-ion or reamen o leukemia.

Science: April 16, 2010


Research Highlighs

7/30/2019 NYUCI_AR10-11_mech29

38/46

THE

CANCER

INSTITUTE AT

NYU LANGONEMEDICAL

CENTER

1 Main Campus ischHospial, including heRia J. and Sanley H. KaplanSem Cell/Bone Marrowransplan Cener

NYU School o Medicine

Rusk Insiue o RehabiliaionMedicine

Charles C. Harris Skin andCancer Pavilion

Sackler Insiue o GraduaeBiomedical Sciences

Cancer Research Cener aJoan and Joel Smilow ResearchCener

Te Helen L. and Marin S.Kimmel Cener or Sem CellBiology a he Skirball Insiueo Biomolecular Medicine

2 Deparmen o EnvironmenalMedicine: Division oBiosaisics

3 Hospial or Join Diseases

4 NYU Cancer Insiue

adminisraive o ces

5 NYU Clinical Cancer Cener

6 Te Sephen D. HasseneldChildrens Cener or Cancerand Blood Disorders

7 Womens Screening Cener(opening 2012)

8 Fuure sie o molecularoncology/cancer genomicslaboraory

9 Joel E. Smilow ComprehensiveProsae Cancer Cener

10 Clinical and ranslaionalScience Insiue Adminisraionand raining Cener

11 Bellevue Hospial Cener

12 Unied Saes Deparmen oVeerans Aairs VA New YorkHarbor Healhcare Sysem

13 New York Universiy College

o Denisry David B. KriserDenal Cener

14 Nelson Insiue oEnvironmenal Medicine

15Woodhull Medical andMenal Healh Cener

16 NYU Langone a ColumbusMedical, Rego Park, NY

17 New York Universiy Collegeo Nursing

18 Fuure collaboraions

Selec Medical Cener environmens include:


NYU Langone Medical Cener Environmens

7/30/2019 NYUCI_AR10-11_mech29

39/46

14

8

18

2

16

7

4

96

5

10

13

1

11

12

17

3

15

All NYU Langone Medical Center environments

are devoted to a culture o excellence in research,

education and patient care.


NYU Langone Medical Cener Environmens

7/30/2019 NYUCI_AR10-11_mech29

40/46

Te Cancer Institute at NYU Langone

Medical Center is especially grateul

to the many individuals, oundations,

corporations and organizations that have

aided our efort in the ght against

cancer. Te generous donors listed here

made gis, commitments and/or event

payments o $10,000 or more in scal

year 2010 (Sept. 1, 2009Aug. 31, 2010).

Te Jerey A. Alman Foundaion

American Cancer Sociey

American Sociey o Hemaology

Anonymous

Apium Oncology

Te Auxiliary o NYU Langone Medical Cener

Avon Foundaion, Inc.

Ellen Banner

Phyllis and Marvin* Barasch

Barlet, McDonough, Basone & Monaghan, LLP

Bernard & Millie Childrens Foundaion

Genie and Bob Birch

Ellen H. Block

Breas Cancer Alliance, Inc.Caesars Alanic Ciy

Cancer Research Insiue

Capial One Bank

Sharon B. Casdin

Susan and Alex Casdin

Cenocor Orho Bioech Services, LLC

Te Chemoherapy Foundaion, Inc.

Wendy and Mathew CherwinChildrens umor Foundaion

PHILANTHROPY


Philanhropy

7/30/2019 NYUCI_AR10-11_mech29

41/46

Clareld Financial Advisors, Inc.

Te Lynne Cohen Foundaion orOvarian Cancer Research

Concern Foundaion

Corcoran SunshineMarkeing Group

Damon Runyon CancerResearch Foundaion

Donny Deusch

Ednas Foundaion o Hope

EPS Foundaion

Fih Avenue Financial

Esae o Isabel Fine

Lori and Laurence FinkCarl and Adele Frischling

Fundacin Cenro NacionalDe InvesigacionesOncolgicas Carlos III

Fundacin Federico

Gabrielles Angel Foundaionor Cancer Research

Gareld Foundaion Inc.

Te Andrew J. GargisoFoundaion Inc.

Te Adam Gaynes Foundaion Inc.

Te Joseph Gluck Foundaion

Alred G. Goldsein

Arlene & Arnold GoldseinFamily Foundaion

Gohic Cabine Cra

rudy Elbaum Gotesman andRober W. Gotesman

Robera and Arnold Greenberg

Ellyn and Michael Greenspan

Greywol Equiy Parners, Inc.

Tierry Gueta a.k.a. Mr. Brainwash

Te Hasseneld Family Foundaion/Alan and Vivien Hasseneld

Sylvia K. Hasseneld

Brian and ania Higgins

Jeremy Hill

Inernaional Associaion or heSudy o Lung Cancer

Inimae Apparel Square Club, Inc.

Marc Jacobs Inernaional, LLC

Joyce Cecelia and J. Seward JohnsonJudih and Irwin Kallman

Esae o Jill Kaplan

KiDS o NYU Foundaion, Inc.

Susan G. Komen or he Cure,Greaer NYC

Kramer Levin Naalis &Frankel LLP

Charles A. Krasne

Kusum Family FoundaionElaine and Kenneh G. Langone

Te Leukemia & Lymphoma Sociey

rudy Lichenberg

Te Harry J. Lloyd Chariable rus

Milon J. Lowensein

Kelly and Sephen Mack

Making Headway Foundaion, Inc.

Edward Mallinckrod Jr. Foundaion

March o Dimes Foundaion

Mr. and Mrs. Eric S. Marks

Ronald Maeo

Melanoma Research Alliance

Melanoma Research Foundaion

Sandra R. and Edward H. Meyer

Consance Milsein

Esae o Gene A. Morin

Esae o Sephen C. Moss

Anna and Franco Muggia

Tomas S. Murphy

Naional Cancer Cener

NC & BC Foundaion, Inc.

Jane and James Neissa

Te Neuberger Berman Foundaion

June Newmark*

Te New York Communiy rus

Opera Gallery on behal oKim and Eric Allouche

Pediaric Cancer Foundaion

Laura and Isaac PerlmuterFoundaion

Te Pew Chariable russ

Te Frances Pope MemorialFoundaion, Inc.

Te Asriel and Marie RackowChariable Foundaion

Radiological Sociey o NorhAmerica Research and EducaionFoundaion

Sondra and Marin* Rappapor

Mr. and Mrs. Herald L. RichMay Ellen & Gerald RiterFoundaion

Paricia Rosenwald andE. John Rosenwald, Jr.

Louise and Joshua Samuelson

Bernard and Irene Schwarz

Juliane Segal Family Foundaion

Devendra Shah

racy and Sanley ShopkornTe Skin Cancer Foundaion

Judy and Marin Sloan

S. Baldricks Foundaion

Debora and Jess Saley

Karin and Michael Sanden

Barbara and Leonard Seiner

Esae o Bernard Sern

Mayo and Elizabeh Cohen Sunzeam Coninuum, Inc.

Teresa and Mark illinger

Lizzie and Jonahan isch

Lisa and Consanine sisera

Sue and Dave Wahrhaig

Te Wasily Family Foundaion, Inc.

Alice P. Weidener

J. Weinsein Foundaion Inc.

Maryann C. Zacharia

* Deceased NYU Cancer I nsiue 2010 / 2011 Repor 39

Philanhropy

7/30/2019 NYUCI_AR10-11_mech29

42/46

FINANCIALS*

(For Fiscal Year 2010)

oal Sources o Suppor

$,,

oal Expenses

$,,

GrantsandContracts

,$115

.3million

Operating,$

8.8

million

DivisionofHematolo

gicMalignancies

andMedicalOncolog

y,$6

.6million

Philanthropy,$4mill

ion

SharedCoreFacilities,$1

.6million

SharedCoreFacilities,$2

.8million

DivisionofHematolo

gicMalignancies

andMedicalOncolog

y,$6

.9million

ClinicalTrialsandTr

anslational

Research

,$7.4million

BasicScienceResearc

h,$

116

.6million

Administration,$

1.5million

PopulationSciences,

CommunityOutreach

,$0

.5million

*Te Cancer Insiue ses he scienic, cli nical and educaional agenda or oncology across he NYU Langone

Medical Cener. Resources and insiuional suppor are allocaed o various deparmens and insiueso und cancer-ocused basic and clinical research iniiaives, aculy recruimen, programs in various disease

areas, he Div ision o Hemaologic Malig nancies and Medical Oncology and new echnologies.


Financials

7/30/2019 NYUCI_AR10-11_mech29

43/46

LEADERSHIP

TEAM

NYU Cancer Insiue

William L. Carroll, MDDirecor, andJulie and Edward J. MinskoProessor o Pediarics

Lauren E. Hacket, MPAExecuive Direcor,Adminisraion

Silvia C. Formeni, MDAssociae Direcor,Clinical Research, and Sandraand Edward H. Meyer Proessor

o Radiaion OncologyRichard B. Hayes, DDS, PhDAssociae Direcor,Populaion Sciences

David E. Levy, PhDAssociae Direcor,Shared Resources, andDr. Louis A. Schneider Proessoro Molecular Pahology

Iman Osman, MDAssociae Direcor, Emerging

Programs and EducaionMark R. Philips, MDAssociae Direcor,Basic Research

Rober J. Schneider, PhDAssociae Direcor,ranslaional Research, andAlber B. Sabin Proessor oMicrobiology and MolecularPahogenesis

James L. Speyer, MD

Associae Direcor, Clinicaland Hospial Operaions

New York Universiy

Martin Lipton, Esq.Chair, Board o rusees

John SextonPresiden

Rober Berne, PhDExecuive Vice Presidenor Healh

NYU LangoneMedical Cener

Kenneth G. LangoneChair, Board o rusees

Robert I. Grossman, MDSaul J. Farber Dean andChie Execuive O cer

Seven B. Abramson, MDSenior Vice Presiden andVice Dean or Educaion, Faculyand Academic Aairs

Dana Bar-Sagi, PhD

Senior Vice Presiden andVice Dean or Science,Chie Scienic O cer

Bernard A. Birnbaum, MDSenior Vice Presiden andVice Dean, Chie o HospialOperaions

Andrew W. Broman, MDSenior Vice Presiden andVice Dean or ClinicalAairs and Sraegy,

Chie Clinical O cer

Michael . BurkeSenior Vice Presiden and

Vice Dean, Corporae ChieFinancial O cer

Annete Johnson, JD, PhDSenior Vice Presiden andVice Dean, General Counsel

Vicki Mach Suna, AIASenior Vice Presiden andVice Dean or Real EsaeDevelopmen and Faciliies

Nader MherabiSenior Vice Presiden and

Vice Dean, Chie InormaionO cer

Nancy SanchezSenior Vice Presiden andVice Dean or Human Resources

Anhony ShorrisSenior Vice Presiden andVice Dean, Chie o Sa

Richard DonoghueSenior Vice Presiden orSraegic Planning and

Business DevelopmenDeborah Loeb BohrenVice Presiden or Communicaionsand Public Aairs

Lisa J. SilvermanVice Presiden or Developmenand Alumni Aairs


Leadership eam

7/30/2019 NYUCI_AR10-11_mech29

44/46

BOARD

OF ADVISORS

Lori Fink, Chair

Ellen Banner

Phyllis Puter Barasch

Susan Block Casdin

Robera Greenberg

Jeremy Hill

James M. Kenny

Kenneh G. Langone

Tomas H. Lee

Edward J. Minsko

Shlomo Perl

Laura Perlmuter

Joshua Samuelson

Sanley Shopkorn

Debora Saley

Joseph S. Seinberg

Kenan urnacioglu

Brian Waler


Board o Advisors

7/30/2019 NYUCI_AR10-11_mech29

45/46

DesignbyAddisonwww.a

ddison.com

Photography:page28:MarkMahaney;page32,

toptobottom:PeterTurnley,RenPrez,GordonCook;

page33,toptobottom:PeterTurnley,GordonCook,JoshuaBright.Writer:DonHeymann

212.731.5000 New Paien Physician Reerral Line212.263.6485 Clinical rials Inormaion

212.731.5002 Mammography and/or Relaed Procedures

212.731.5198 Lucille Robers Wellness Bouiquemanaged by Underneah I All

212.731.5452 Lynne Cohen Foundaion and Caringogeher Projec or Women wih Increased Risk or Cancer/Clinical Cancer Cener

212.263.3198 Lynne Cohen Foundaion and Caringogeher Projec or Women wih Increased Risk or Cancer/Bellevue Hospial Cener

212.263.8400 Sephen D. Hasseneld ChildrensCener or Cancer and Blood Disorders

212.731.5345 100 Women in Hedge FundsNaional Ovarian Cancer Early Deecion Program

212.731.5480 NYU Clinical Cancer CenerSuppor Group Inormaion Line

212.263.6342 Communiy Oureach Programs &Speakers Bureau

212.404.3555 Media Inquiries

212.404.3640 O ce o Developmen

212.263.3276 NY UCI O ce o he Direcor

Imporan Phone Numbers

155,000+paien visis in FY2010

(oal among our major sies).

151,170 sq. .o dedicaed space, a 400%

increase since 2002.

$112.6million in researchunding inclusive o$24 million rom he

Naional Cancer Insiue.

227invesigaors workingon cancer iniiaives.

150+oncology clinical

rials available.

20%paien paricipaion

in clinical rials, comparedo 4% naional average.

5,000communiy members,paiens and healhcare

proessionals benerom our Communiy

Oureach and Educaionprograms.

NYU Cancer Insiue Facs & Figures

NYU Langone Medical Cener has again atained Magne recogniion as par o he American Nurses

Credenialing Ceners (ANCC) Magne Recogniion Program. Te ANCCs Magne Recogniion Programrecognizes healhcare organizaions ha demonsrae excellence in nursing services. Magne recogniion

is he highes naional honor or nursing excellence, serving as he gold sandard or nursing pracice.

A publicaion o Te Cancer Insiue a NYU Langone Medical Cener.

Produced by he O ce o Communicaions and Public Aairs.

7/30/2019 NYUCI_AR10-11_mech29

46/46

NYU Cancer Insiue

522 Firs Avenue, Smilow 1201New York, New York 10016

www.NYUCI.org

An NCI-designaed Cancer Cener

nyuci_ar10-11_mech29

Documents